About Larimar Therapeutics
Clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Bala Cynwyd, PA
- Founded
- 2016
- Company type
- Public Company
- Company profile name
- Larimar Therapeutics Inc.
Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Specialties
- Biotechnology and Rare Disease
Company locations
Three Bala Plaza East, Suite 506, Bala Cynwyd, PA 19004, US
4500 East 75th Street, Indianapolis, Indiana 46250, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Biotechnology
- Medical
- Therapeutics
On LinkedIn
- Followers
- 4,378
- People linked to this company
- 86
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
721,680,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.